KISSEI

  • Link
  • Japanese Page

Change Font Size

  • normal
  • large
  • About Kissei
  • Research & Development
  • News Release
  • Investor Relations
  • Sustainability

About Kissei

Research & Development

News Release

Investor Relations

Sustainability

kissei

  • About Kissei
  • Research & Development
  • News Release
  • Investor Relations
  • Sustainability
  • Link
  • Japanese Page
  • English
  • Message
  • Philosophy
  • Company Profile
  • Our Business
  • KISSEI's History
  • Corporate Governance
  • About R&D
  • Central Research Laboratories
  • Safety Research Laboratories
  • Joetsu Chemical Laboratories
  • Pharmaceutical Laboratories
  • R&D Pipeline
  • Business Results
  • Annual Report
  • Shareholders Meeting
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • CSR Management
  • SDGs
  • Materiality
  • Compliance
  • Social Contribution Activities
  • Environmental Initiatives
  • Consideration for Employees
  • ESG Data
  • Message
  • Philosophy
  • Company Profile
  • Our Business
  • KISSEI's History
  • Corporate Governance
  • About R&D
  • Central Research Laboratories
  • Safety Research Laboratories
  • Joetsu Chemical Laboratories
  • Pharmaceutical Laboratories
  • R&D Pipeline
  • Business Results
  • Annual Report
  • Shareholders Meeting
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • CSR Management
  • SDGs
  • Materiality
  • Compliance
  • Social Contribution Activities
  • Environmental Initiatives
  • Consideration for Employees
  • ESG Data
  • Looking Towards Tomorrow’s Health

    About Kissei

    What’s new

    More
    • August 1, 2022

      R&D Pipeline as of August 2022
    • August 1, 2022

      ​The First Quarter of FY2022 (August 1, 2022)
    • May 10, 2022

      Financial Results(May 10, 2022)​
    • February 1, 2022

      The Third Quarter of FY2021(April 2021- December 2021)
    • November 9, 2021

      The Second Quarter of FY2021 (April 2021 - September 2021)

    News Release

    More
    • July 27, 2022

      Notice on the release by ObsEva, the licensee of "Linzagolix", GnRH antagonist
    • July 6, 2022

      Kissei Initiates Phase III Clinical Trial for GnRH antagonist Linzagolix in Japanese Patients with uterine fibroids
    • June 17, 2022

      Marketing authorization in Europe for GnRH antagonist Linzagolix
    • June 6, 2022

      Launch of TAVNEOS® Capsules 10mg, a selective Complement C5a Receptor Antagonist
    • May 30, 2022

      "CAROGRA® Tablets", Launched in Japan for Treatment of Ulcerative Colitis
      - The World-First Orally Available α4 Integrin Antagonist Come onto the Market -
    • About Kissei

    • Research &
      Development

    • Investor Relations

    • About Kissei
    • Research & Development
    • News Release
    • Investor Relations
    • Terms of Use
    • Privacy Policy
    © 2012- Kissei Pharmaceutical Co., Ltd. All rights reserved.
    キッセイ薬品工業株式会社

    Thank you for visiting the Kissei website.
    You are now moving to an external website.
    (A new window will be opened.)

    Access the link